Registry update — unassessed
Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 8, 2025 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- This describes a trial design rather than reported results; efficacy of senolytics in MS cannot be determined from this abstract alone. The study was designed to assess safety and feasibility, not to establish clinical benefit. No sample size, effect sizes, or outcome data are reported.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 12 months
- Population
- Adults with secondary progressive multiple sclerosis (SPMS), aged 50-85 years, not currently taking MS disease-modifying therapy, with worsening MS symptoms
- Primary outcome
- Safety and feasibility of senolytic therapy in patients with secondary progressive MS
- Effect size
- —
- Significance
- Not reported
- Journal
- Ohio State University
- Published
- Dec 8, 2025
Sources
Primary source
- Ohio State University ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS
The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse
People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months
Participants will also be followed for one year from enrollment to monitor for treatment effects
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.